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Children and Adolescents
Thomas G. Gross,1 Gregory A. Hale,2 Wensheng He,3 Bruce M. Camitta,4 Jean E. Sanders,5
Mitchell S. Cairo,6 Robert J. Hayashi,7 Amanda M. Termuhlen,1 Mei-Jie Zhang,3
Stella M. Davies,8 Mary Eapen3,4We examined the role of hematopoietic stem cell transplantation (HSCT) for patients aged# 18 years with
refractory or recurrent Burkitt (n5 41), lymphoblastic (n5 53), diffuse large B cell (DLBCL; n5 52), and
anaplastic large cell lymphoma (n5 36), receiving autologous (n5 90) or allogeneic (n5 92; 43 matched
sibling and 49 unrelated donor) HSCT in 1990-2005. Risk factors affecting event-free survival (EFS) were
evaluated using stratified Cox regression. Characteristics of allogeneic and autologous HSCT recipients
were similar. Allogeneic donor HSCTwas more likely to use irradiation-containing conditioning regimens,
bone marrow (BM) stem cells, be performed in more recent years, and for lymphoblastic lymphoma. EFS
rates were lower for patients not in complete remission at HSCT, regardless of donor type. After adjusting
for disease status, 5-year EFS were similar after allogeneic and autologous HSCT for DLBCL (50% vs 52%),
Burkitt (31% vs 27%), and anaplastic large cell lymphoma (46% vs 35%). However, EFS was higher for lympho-
blastic lymphoma, after allogeneic HSCT (40% vs 4%; P\.01). Predictors of EFS for progressive or recurrent
disease after HSCT included disease status at HSCTand use of allogeneic donor for lymphoblastic lymphoma.
These data were unable to demonstrate a difference in outcome by donor type for the other histological
subtypes.
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More than 95% of pediatric non-Hodgkin lym-
phoma (NHL) is high-grade disease, in contrast to
adult NHL, in which low-grade and indolent disease
predominate [1]. The 4 major histological subtypes
of NHL in children and adolescents are Burkitt, lym-
phoblastic, diffuse large B cell (DLBCL), and anaplas-
tic large cell lymphoma [1]. Current results using
intensive chemotherapy regimens are excellent even for
patients with stage III/IV disease. Long-term event-
free survival (EFS) is between 60% and 90%, depend-
ing on histological subtype [2-9]. Long-term survival
is only 10%-20% for refractory or recurrent Burkitt,
DLBCL, and lymphoblastic lymphoma [10-13], but
up to 60% for refractory or recurrent anaplastic large
cell lymphoma [13,14].
A Children’s Cancer Group (CCG) study for
relapsed pediatric lymphoma found an EFS of 25%
for all children with NHL, and for those with chemo-
sensitive disease, EFS was similar with or without
autologous hematopoietic stem cell transplantation223
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ogy (SFOP) reported a 3-year disease-free survival
(DFS) of 45% for relapsed anaplastic large cell lym-
phoma with similar DFS after chemotherapy or autol-
ogous HSCT for patients in second complete
remission (CR2) [14]. In another report from the
SFOP, for patients with relapsed mature B-cell NHL
(diffuse large B cell [DLBCL] and Burkitt lymphoma),
all who did not undergo HSCT succumbed to the dis-
ease, and in those who underwent HSCT, the 3-year
overall survival was only 27% [16]. The European
Lymphoma Bone Marrow Transplantation Registry
reported a 5-year EFS of 40% for 89 pediatric patients
with refractory/recurrent Burkitt or DLBCL who un-
derwent autologous HSCT [17]. None of the patients
with primary refractory disease or chemoresistant re-
lapse survived. Because their study spanned the period
1979-1991, only 10 patients received what would be
considered modern first-line therapy, thereby raising
concerns as to the applicability of their report in the
current era. Several other reports on HSCT for pedi-
atric NHL have included more than one histological
subtype, are limited to relatively small numbers of pa-
tients, or have included children in a larger series that
included adults. Consequently, the role of allogeneic
HSCT compared with autologous HSCT for patients
in CR2 or recurrent NHL is of interest to the pediatric
oncologist [13,15,18-24]. The purposes of the present
study were to identify prognostic factors affecting out-
comes and to assess the optimal donor source for chil-
dren and adolescents treated with HSCT for
refractory or recurrent NHL.PATIENTS AND METHODS
Data Collection
Data on patients undergoing HSCT were obtained
from the Statistical Center of the Center for Interna-
tional Blood and Marrow Transplant Research
(CIBMTR). The CIBMTR is a voluntary working group
of more than 500 transplantation centers worldwide that
report patient, disease, and transplant characteristics and
outcome data on consecutive transplantations to a Statis-
tical Center at the Medical College of Wisconsin. The
Institutional Review Board of the Medical College of
Wisconsin approved the study design.
Inclusion Criteria
The study included patients aged# 18 years in
CR2 or subsequent CR (ie, complete disappearance
of all known disease for$ 4 weeks) and refractory/re-
current NHL (ie, relapse or progression, defined as in-
crease in size of sites of disease [$ 25% increase in
largest diameter] and/or new disease sites and/or histo-
logical evidence of disease) who received an autologous
or allogeneic HSCT as their first transplantation. Pa-tients who had received an autologous transplant be-
fore allogeneic transplantation were excluded
(n5 13). All patients received a myeloablative (MA)
transplantation conditioning regimen and underwent
transplantation between 1990 and 2005. Ninety autol-
ogous transplant recipients and 92 allogeneic trans-
plant recipients were eligible.
Study Endpoints
Neutrophil recovery was defined as achieving an
absolute neutrophil count (ANC) of$ 0.5  109/L
for 3 consecutive days, and platelet recovery and un-
supported platelet count. 20 109/L for 7 days. The
incidence of grade II, III, and IV acute graft-versus-
host disease (aGVHD) [25] and chronic GVHD
(cGVHD) [26] were determined for allogeneic HSCT.
Deaths occurring in continuous remission were de-
fined as treatment-related mortality (TRM). Progres-
sion was defined as progressive disease ($ 28 days
from HCST) or recurrent disease in patients who
achieved remission posttransplantation. Progression
could follow a period of ‘‘stable’’ disease posttransplan-
tation, or partial remission. Progression/recurrence
represented an increase in size of sites of disease ($
25% increase in largest diameter) and/or new disease
sites and/or histological evidence of disease. EFS was
defined as survival without recurrent or progression
of lymphoma.
Statistical Analysis
The probability of EFS was calculated with the
Kaplan-Meier estimator [27]. For analysis of EFS, re-
lapse or progression of disease or death from any cause
was considered an event, and surviving patients were
censored at last follow-up. The incidence of neutro-
phil and platelet recovery, aGVHD and cGVHD,
TRM, and relapse/progression were calculated using
the cumulative-incidence-function method [27]. For
hematopoietic recovery and GVHD, death without
the event was the competing event. For TRM,
relapse/progression was the competing event, and for
relapse/progression, TRM was the competing event.
Confidence intervals (CIs) were calculated using log-
transformation.
Stratified Cox regression models were built for
analysis of risk factors for relapse/progression and
EFS [28]. Models were stratified by disease (Burkitt,
lymphoblastic, DLBCL, or anaplastic large cell lym-
phoma) and donor type (autologous or allogeneic).
Multivariate models were built using stepwise forward
selection, with a P value of# .05 considered to indicate
statistical significance. Our primary objective was to
determine whether there was an advantage to offering
an allogeneic HSCT over autologous HSCT for pa-
tients with refractory/recurrent NHL. Other variables
considered were age (# 10 years vs 11-18 years), sex,
Table 1. Patient, disease, and transplant characteristics
Autologous,
n (%)
Allogeneic,
n (%) P value
Number of patients 90 92
Age at transplantation, years
# 10 26 (29) 29 (32)
11-18 64 (71) 63 (68)
Performance score before
transplantation
.12
< 90% 17 (19) 29 (32)
$ 90% 70 (78) 60 (65)
Unknown 3 (3) 3 (3)
Disease < .001
Diffuse large cell 35 (38) 17 (19)
Lymphoblastic 14 (16) 39 (42)
Burkitt 17 (19) 24 (26)
Anaplastic 24 (27) 12 (13)
Interval from diagnosis to
transplantation
.54
< 6 months 9 (10) 5 (5)
6-12 months 30 (33) 33 (36)
$ 12 months 51 (57) 54 (59)
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diagnosis to HSCT (\6 vs 6-12 vs. 12 months), dis-
ease status ($ CR2 vs not in remission), graft type
(bone marrow [BM] vs peripheral blood [PB]), and
year of HSCT (1990-1994 vs 1995-1999 vs 2000-
2005). Allogeneic transplants were grouped together
regardless of donor type. Before combining HLA-
matched sibling and unrelated donor transplant recip-
ients, analyses were preformed to detect differences in
transplantation outcome; none were found except for a
higher incidence of grade II-IV aGVHD in unrelated
donor transplant recipients (data not shown). There
was no difference in survival rates between recipients
of HLA-matched sibling and unrelated donor trans-
plants. No effect of transplantation center on EFS
was found [29]. All analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC). All P values
are 2-sided.Disease status before
transplantation
.65
$CR2 43 (48) 47 (51)
Relapse or progression 47 (52) 45 (49)
Interval from diagnosis to first
relapse*
.18
< 6 months 15 (20) 29 (32)
6-12 months 23 (30) 21 (23)
> 12 months 38 (50) 40 (44)
Conditioning regimen < .001
TBI + cyclophosphamide 25 (28) 74 (80)
TBI + other agents 10 (11) 5 (6)
Busulfan + cyclophosphamide 4 (5) 13 (2)
Cyclophosphamide + etoposide 26 (29) 0
* Other 25 (27) 0
Graft type < .001
Bone marrow 39 (43) 75 (82)
Peripheral blood 51 (57) 17 (18)
Year of transplantation < .001
1990-1994 47 (52) 12 (13)
1995-2005 43 (48) 80 (87)
Type of donor
HLA-identical sibling NA 43 (47)
Unrelated† 49 (53)
Median (range) follow-up, months 71 (2-142) 43 (2-157)
CR indicated complete remission; TBI, total body irradiation.
*Excludes patients who did not achieve first CR; 2 allogeneic transplant
recipients and 14 autologous transplant recipients had progressive dis-
ease with front-line therapy and proceeded to transplantation without
achieving CR.
†Nine matched URD, 40 mismatched URD.RESULTS
Table 1 sumarizes patient, disease, and transplant
characteristics by donor type. Patients with lympho-
blastic lymphoma were more likely than those with
the other histological subtypes to undergo allogeneic
HSCT. Allogeneic HSCT recipients were more likely
to receive an irradiation-containing conditioning reg-
imen, receive a BM graft, and to have undergone trans-
plantation recently. Sixteen patients underwent
HSCT for primary induction failure, 14 of whom re-
ceived an autologous transplant. Approximately 65%
of the autologous and allogeneic transplant recipients
received 1 or 2 lines of therapy before transplantation,
and 35% received 3-5 lines of therapy before trans-
plantation. More than half of the allogeneic recipients
received a graft from an unrelated donor, the majority
of which were HLA-mismatched. Twenty percent of
allogeneic transplant recipients received antithymo-
cyte globulin (ATG) as part of transplantation condi-
tioning. The median follow-up of surviving patients
is approximately 6 years after autologous HSCT and
4.5 years after allogeneic HSCT.
Hematopoietic Recovery
The incidence of neutrophil recovery (day128) was
87% (95% CI5 73%-96%) after allogeneic HSCT
and 74% (95% CI5 62%-85%) after autologous
HSCT. The corresponding incidences at day 1100
were 93% (95% CI5 77%-100%) and 90% (95%
CI5 75%-99%), respectively. The incidence of plate-
let recovery (day 1100) was 67% (95% CI5 54%-
78%) following allogeneic HSCT and 76% (95%
CI5 62%-88%) following autologous HSCT. In 47
patients, neutrophil and/or platelet recovery was not
achieved because of either disease progression or death
from a transplantation-related complication.Acute and Chronic GVHD
Among allogeneic HSCT recipients, the incidence
of grade II-IV aGVHD at day 1100 was 43% (95%
CI5 33%-54%; grade II, n5 22; grade III, n5 11;
grade IV, n5 5). Fourteen patients developed
cGVHD; the 5-year incidence of cGVHD was 16%
(95% CI5 9%-25%).Transplantation-Related Mortality
The 1- and 5-year TRM rates were similar after
autologous and allogeneic HSCT: 14% (95%
CI5 7%-22%) and 24% (95% CI5 16%-34%)
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Figure 1. The probability of recurrent or progressive disease after allogeneic and autologous transplantation for Non-Hodgkin lymphoma: Diffuse
Large Cell (1A), Lymphoblastic (1B), Burkitt (1C) and Anaplastic (1D).
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spectively, and 17% (95% CI5 9%-25%) and 25%
(95% CI5 17%-35%) (P5 .15) at 1 and 5 years after
allogeneic HSCT, respectively.Relapse or Progression
Relapse or progression of disease occurred in 42
patients after autologous HSCT and in 32 patients
after allogeneic HSCT. The risk of recurrent or pro-
gressive disease was higher in patients who were not
in CR at transplantation (relative risk [RR]5 2.46;
95% CI5 1.50-4.04; P \ .01), regardless of donor
type. The 90 patients (allogeneic and autologous
transplant recipients) who underwent transplantation
in CR included 77 in CR2 and 13 in CR3. Given the
very few patients who underwent transplantation in
CR3, we are unable to provide relapse rates separately
for patients in CR2 and CR3. There were no signifi-
cant differences in the 5-year probability of relapse/
progression by donor type for DLBCL, Burkitt
lymphoma, and anaplastic large cell lymphoma(Figure 1A, C, and D). The apparent decrease in
progression seen in patients with anaplastic large cell
lymphoma who underwent allogeneic HSCT did not
reach statistical significance. For patients with lym-
phoblastic lymphoma, the 5-year probability of
relapse/progression was lower after allogeneic
HSCT compared with autologous HSCT (Figure 1B).Event-Free Survival
In multivariate analysis, risks of treatment failure
(ie, relapse/progression or death; inverse of EFS)
were higher for patients who were not in CR at the
time of transplantation (RR5 2.42; 95% CI5 1.62-
3.62; P\ .01) regardless of donor type, with a 5-year
EFS of 28% for autologous HSCT and 20% for allo-
geneic HSCT. The corresponding probabilities for
patients who underwent HSCT in CR2 or CR3 were
40% and 57%, respectively. No effect of the duration
of CR1 on EFS was found (RR5 0.80; 95%
CI5 0.58-1.10; P5 .16 in patients with a CR1 dura-
tion of .12 months compared to# 12 months). The
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Figure 2. The probability of event-free survival after allogeneic and autologous transplantation for Non-Hodgkin lymphoma: Diffuse Large Cell (1A),
Lymphoblastic (1B), Burkitt (1C) and Anaplastic (1D).
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DLBCL, and anaplastic large cell lymphoma were
similar (Figure 2A, C, and D). The 5-year probability
of EFS was higher after allogeneic HSCT compared
with autologous HSCT for patients with lymphoblas-
tic lymphoma (Figure 2B). Recurrent or progressive
disease was the most frequent cause of death after
autologous transplantation (34 of 48 deaths were due
to recurrent or progressive disease; 70%) compared
to allogeneic transplantation (29 of 50 deaths were
due to recurrent or progressive disease; 58%). Deaths
from transplantation-related complications were more
frequent after allogeneic HSCT (infection, n5 8 vs 3;
interstitial pneumonitis/adult respiratory syndrome;
n5 4 vs 6; GVHD, n5 1 vs 0; organ failure, n5 6 vs
3; other causes, n5 3 vs 2).DISCUSSION
The purpose of this study was to identify prognos-
tic factors, including the optimal donor source, in
children and adolescents with refractory/recurrentNHL undergoing HSCT. With the current up-front
chemotherapy regimens, outcome for pediatric NHL
is excellent even for those with advanced (stage III or
IV) disease [2-9]. Salvage of patients with refractory
or recurrent disease remains very poor, however
[10-14]. Because data on front-line therapies for this
cohort were not available, patients who underwent
HSCT before 1990—before the advent of more
aggressive front-line therapies—were excluded from
the analysis. EFS was worse for patients not in CR at
the time of HSCT independent of donor type, and
EFS was superior for patents with lymphoblastic
lymphoma after allogeneic HSCT. Our findings con-
firm and extend the observations of several previous
studies. First, salvage rates are higher for large cell
lymphoma (DLBCL or anaplastic) compared with
small cell lymphoma (Burkitt and lymphoblastic). Sec-
ond, disease status at transplantation is a strong prog-
nostic indicator [16-18,20,24]. Of note, for patients
not in CR at the time of transplantation, there appears
to be no difference in 5-year EFS after allogeneic
HSCT and autologous HSCT (20% vs 28%). Our
data also illustrate the complexities of extrapolating
228 Biol Blood Marrow Transplant 16:223-230, 2010T. G. Gross et al.results from reports on HSCT in adults with NHL.
Our findings differ from those of a study by Levine
et al. [21] comparing allogeneic and autologous
HSCT for lymphoblastic lymphoma. In that study,
fewer than 20% of the study population was aged# 18
years [21]; consequently, the higher TRM after alloge-
neic HSCT and the absence of a significant difference
in EFS after autologous and allogeneic HSCT would
be expected and explained by the inclusion of mostly
older patients.
Although we found a significantly lower progres-
sion rate and improved EFS in patients with lympho-
blastic lymphoma after allogeneic HSCT, we were
unable to demonstrate a superiority of donor type
(autologous vs allogeneic) for Burkitt, DLBCL, or an-
aplastic large cell lymphoma. It is tempting to specu-
late that a graft-versus-lymphoma (GVL) effect exists
in lymphoblastic lymphoma and perhaps in anaplastic
large cell lymphoma as well; however, in our cohort,
the numbers were insufficient to allow us to correlate
EFS or progression rate with GVHD or to allow
examination of differences in EFS for related versus
unrelated donor transplant recipients. A recent Ber-
lin-Frankfurt-Munster (BFM) report suggested a bene-
fit of allogeneic HSCT for high-risk anaplastic large
cell lymphoma, especially in patients who have
relapsed after autologous HSCT [22]. Again, small
numbers kept us from examining for an effect of autol-
ogous HSCT before allogeneic HSCT.
There are inherent weaknesses in all studies that
use data collected by transplantation registries. The
outcome of patients who did not undergo HSCT
during the study period is unknown, and the decision
to offer HSCT or donor choice was not reported.
Patients were more likely to receive autologous
HSCT early in the study period. This is likely ex-
plained by a widespread perception that allogeneic
HSCT is superior for pediatric relapsed/refractory
NHL. Even though we found no differences in the
number of lines of therapy for autologous and alloge-
neic transplant recipients, in the absence of detailed in-
formation on front-line therapies, it is conceivable that
the HSCT results in this cohort are biased, as patients
may have received front-lines therapies of varying in-
tensity, which could influence EFS after HSCT. We
also can speculate that the superior outcome for allo-
geneic HSCT in the later time period because of
improved donor–recipient HLA-matching and im-
proved supportive care, resulting in lower TRM.
Although the numbers are small, no differences in out-
come over time were observed in the current analysis.
Achieving disease control can be very difficult and
short-lived, especially in relapsed Burkitt or lympho-
blastic lymphoma, and this may influence donor selec-
tion. There may exist a bias favoring allogeneic
HSCT, as unrelated donor HSCT (50% of allogeneic
HSCT) was likely pursued only in patients with moreresponsive disease and durable remissions. We found
no difference in time to transplantation between autol-
ogous and allogeneic HSCT in this cohort, however.
Disease characteristics, such as involvement of site(s)
at diagnosis and relapse, and their impact on HSCT
outcome were not examined, because these data were
not adequately captured.
Despite these limitations, however, our study pop-
ulation represents the largest pediatric NHL cohort to
have received HSCT as salvage therapy. It is unlikely
that a randomized study will ever be done to assess
the benefit of autologous versus allogeneic HSCT in
pediatric NHL, because of the relatively small numbers
of patients and the inherent problems of donor avail-
ability when considering allogeneic HSCT. Therefore,
using data collected by transplantation registries offer
an alternative for studying treatment choices, although
this is not ideal. We demonstrate that both autologous
and allogeneic HSCT can be effective in salvaging
children and adolescents with refractory or recurrent
NHL and results are superior if CR can be achieved
before HSCT. In addition, the data suggest that an
allogeneic donor is preferred for patients with lympho-
blastic lymphoma.ACKNOWLEDGMENTS
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